Landos Biopharma, Inc. (LABP): Price and Financial Metrics


Landos Biopharma, Inc. (LABP): $0.72

0.11 (+17.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LABP to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LABP Stock Price Chart Interactive Chart >

Price chart for LABP

LABP Price/Volume Stats

Current price $0.72 52-week high $16.17
Prev. close $0.61 52-week low $0.55
Day low $0.58 Volume 92,300
Day high $0.75 Avg. volume 103,422
50-day MA $1.12 Dividend yield N/A
200-day MA $6.79 Market Cap 28.98M

Landos Biopharma, Inc. (LABP) Company Bio


Landos Biopharma, Inc. operates as a pharmaceutical company. The Company discovers and develops oral therapeutics for patients with autoimmune diseases. Landos Biopharma serves customers worldwide.


LABP Latest News Stream


Event/Time News Detail
Loading, please wait...

LABP Latest Social Stream


Loading social stream, please wait...

View Full LABP Social Stream

Latest LABP News From Around the Web

Below are the latest news stories about Landos Biopharma Inc that investors may wish to consider to help them evaluate LABP as an investment opportunity.

Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythemat...

Benzinga | February 9, 2022

What Percentage Of Landos Biopharma, Inc. (NASDAQ:LABP) Shares Do Insiders Own?

Every investor in Landos Biopharma, Inc. ( NASDAQ:LABP ) should be aware of the most powerful shareholder groups...

Yahoo | February 4, 2022

Analysts Offer Insights on Healthcare Companies: Danaher (DHR) and Landos Biopharma (LABP)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Danaher (DHR – Research Report) and Landos Biopharma (LABP – Research Report). Danaher (DHR) In a report issued on December 31, Tycho Peterson from J.P. Morgan maintained a Buy rating on Danaher, with a price target of $400.00. The company's shares closed last Friday at $329.01, close to its 52-week high of $333.96. According to TipRanks.

Christine Brown on TipRanks | January 2, 2022

Landos Biopharma (NASDAQ:LABP) Lowered to “Hold” at Zacks Investment Research

Landos Biopharma (NASDAQ:LABP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Tuesday, Zacks.com reports. According to Zacks, “Landos Biopharma Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. Landos Biopharma Inc. […]

Dakota Financial News | December 23, 2021

Insider Selling: Landos Biopharma, Inc. (NASDAQ:LABP) Major Shareholder Sells 43,000 Shares of Stock

Landos Biopharma, Inc. (NASDAQ:LABP) major shareholder Josep Bassaganya-Riera sold 43,000 shares of the stock in a transaction on Wednesday, December 15th. The shares were sold at an average price of $5.02, for a total value of $215,860.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through []

Transcript Daily | December 15, 2021

Read More 'LABP' Stories Here

LABP Price Returns

1-mo -35.71%
3-mo -66.04%
6-mo -90.16%
1-year -93.44%
3-year N/A
5-year N/A
YTD -85.00%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6302 seconds.